BANNER LIFE SCIENCES
PharmaBANNER LIFE SCIENCES is a pharmaceutical company focused on Neurology. Key products include BAFIERTAM.
BANNER LIFE SCIENCES's Key Drugs
BANNER LIFE SCIENCES's core commercial portfolio centers on BAFIERTAM, spanning Neurology — its most strategically important drugs approved in the last 15 years.
BANNER LIFE SCIENCES's Recent FDA Approvals
New NDA/BLA approvals for BANNER LIFE SCIENCES over the last two years — novel drugs only, excluding generics and label supplements.
BANNER LIFE SCIENCES's Therapeutic Areas
BANNER LIFE SCIENCES's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BANNER LIFE SCIENCES's Top Competitors
BANNER LIFE SCIENCES's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BANNER LIFE SCIENCES Pipeline Snapshot
BANNER LIFE SCIENCES has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BAFIERTAM leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-04-28
- Latest
- 2024-09-26
- Applications
- 1